TECHNOLOGY SCOUTING / PHASE 2 EXAMPLE 01
Alternative Sterilisation Routes for a Single Use Diagnostic Cartridge
How a medical device team could identify realistic alternatives to an established ethylene oxide process without treating every non EtO modality as technically interchangeable.
DEVICE PROFILE
SCOUTING HORIZON
EXAMPLE FIELD
ACTION QUEUE
PCR diagnostic cartridge
Five week desk study
46 initial leads
3 advance | 2 watch
All quantities shown in this example are hypothetical.
Background and decision need
A diagnostics manufacturer was preparing a next generation, single use molecular test cartridge for expanded production. The hypothetical device combined a cyclic olefin polymer microfluidic body, a transparent optical window, foil and elastomer seals, and four wells containing lyophilised enzymatic reagents. The design target included a maximum process temperature of 45°C, a sterility assurance level of 10⁻⁶, maintenance of optical transmission, and a 24 month shelf life.
The current product family used a fixed chamber ethylene oxide process through an external sterilisation provider. The R&D team did not want a general review of sterilisation methods. It needed to know which external technologies and process architectures were credible enough to enter a controlled feasibility programme, and which should be excluded before provider discussions or laboratory work began.
DECISION QUESTION Which sterilisation routes, provider capabilities or changes to the sterilisation boundary could reduce dependence on the existing EtO route while protecting microbial assurance, cartridge function, reagent activity, package integrity and the regulatory pathway?
Why the problem required technical scouting
- A modality can be recognised and widely used while remaining unsuitable for a particular material set, channel geometry, reagent system or package configuration.
- Changing sterilisation may affect device performance, biocompatibility, residuals, dose response, package integrity and the content needed in a regulatory submission.
- The product mixed sterilisation tolerant hardware with sensitive biological reagents, making the location of the sterilisation boundary as important as the modality itself.
- Availability at a contract facility, chamber or source configuration, load geometry, scale and the provider’s validation experience could determine whether a technically plausible route was actionable.
Regulatory context retained in the brief
FDA recognised vaporised hydrogen peroxide as an Established Category A method in January 2024 and continues to support sterilisation change and radiation master file programmes. FDA sterilisation overview | FDA VH2O2 update
As of August 2026, EPA had proposed reconsideration of the 2024 commercial steriliser rule. The example therefore treats EtO policy direction and capacity exposure as conditions to monitor, not as a settled prediction. EPA proposed reconsideration
TECHNOLOGY SCOUTING / RESEARCH METHOD
The scouting brief converted the device into search rules
The research team first separated essential requirements from preferences. The search did not begin with a list of sterilisation vendors. It began with the product surfaces, materials, biological contents, process limits, sterile barrier, likely regulatory route and manufacturing sequence that every candidate would have to address.
Brief element | Example research definition |
|---|---|
Required function | Validated microbial inactivation for the defined product or component boundary, with a realistic route to routine processing. |
Hard constraints | Process temperature at or below 45°C; no unacceptable optical haze, bond failure, channel distortion or reagent loss; compatible sterile barrier and load configuration. |
Evidence threshold | Regulator or standard recognition where applicable, relevant material or device evidence, a visible validation route, and an identifiable provider or capability pathway. |
Included routes | Vaporised hydrogen peroxide, gamma, X ray, electron beam, selected chemical modalities, component sterilisation and aseptic assembly architectures. |
Early exclusions | Routes requiring temperatures beyond the device limit; claims without device relevant evidence; providers lacking a visible path to the required scale or configuration. |
How the candidate field was built and tested
Workstream | Method applied | Control used |
|---|---|---|
Product boundary model | Map polymer body, optical path, microchannels, adhesives, seals, reagent wells, pouch and manufacturing sequence. Identify which items must be sterile and when. | Prevents the research from assuming the whole finished cartridge must receive the same treatment. |
Modality and standards scan | Review FDA category treatment, recognised consensus standards, sterilisation change programmes, technical literature, material compatibility guidance and provider process descriptions. | A recognised method is recorded as regulatory context, not proof of product fit. |
Candidate discovery | Search modality developers, contract sterilisation capabilities, equipment platforms, research groups, patents and application studies using function, geometry, material and process terms. | Duplicate entities, repeated announcements and unsupported commercial claims are removed. |
Evidence gate | Compare penetration or dose delivery, material and reagent compatibility, process temperature, package implications, validation path, scale signals and visible access route. | Each card states what is known, inferred, claimed and still untested. |
Action translation | Assign advance, watch or hold status and define the smallest experiment or specialist question that could change the decision. | The output prioritises next work instead of suggesting a direct process conversion. |
Example screening funnel
DISCOVER
SCREEN
COMPARE
ACT
46 leads
modalities and actors
17 in scope
after hard exclusions
8 evidence cards
with unresolved questions
3 advance
2 watch | 3 hold
TECHNOLOGY SCOUTING / EXAMPLE OUTPUT
Candidate route triage
The example output did not declare a winning sterilisation technology. It showed where each route could enter a feasibility programme, the product boundary to which it might apply and the unresolved question that would determine whether it progressed.
Route | Why it remained relevant | Critical unresolved question | Status |
|---|---|---|---|
Vaporised hydrogen peroxide | FDA Category A recognition and ISO 22441:2022 created a clearer regulatory and validation reference point. Low temperature processing was relevant to the dry cartridge hardware. | Can the sterilant penetrate the selected channel and packaging configuration without unacceptable interaction with seals, surfaces or residual sensitive reagents? | ADVANCE |
X ray | An established radiation route with potential for pallet or box level processing and no radioisotope source. It warranted examination for empty cartridge and packaged hardware configurations. | What dose window preserves optical transmission, polymer strength, bond integrity and reagent performance after ageing? | ADVANCE |
Component sterilisation plus aseptic reagent loading | Changing the sterilisation boundary could separate compatible dry hardware from radiation or oxidant sensitive biological contents. | Can the manufacturing sequence, environmental control, closure step and package system maintain the required sterile state at commercial scale? | ADVANCE |
Electron beam | High throughput and an established radiation category made the route relevant for shallow, low density product configurations. | Can penetration and dose uniformity be demonstrated for the cartridge, pouch and proposed load while retaining reagent and material performance? | WATCH |
Gamma | Established standards and broad provider experience made gamma an important comparator rather than an automatic choice. | Does the cumulative dose and exposure profile create unacceptable change in enzymes, adhesives, optical components or accelerated ageing results? | WATCH |
Nitrogen dioxide or supercritical CO2 | FDA has publicly discussed exploration of such alternatives for certain medical devices, so they were retained as emerging routes. | Is there device relevant evidence, a credible regulatory path and accessible commercial scale capability for this specific cartridge? | HOLD |
The most useful finding was a boundary option
The evidence suggested that the team should not frame the choice only as “EtO versus another terminal method.” A split process could allow the empty cartridge hardware to receive a compatible sterilisation process before sensitive reagents were introduced under a qualified aseptic operation. This option would affect manufacturing design, package strategy and validation, so it was advanced as an architecture for feasibility work rather than a recommendation.
DRY HARDWARE
STERILISATION
SENSITIVE REAGENTS
FINAL BARRIER
Mould, bond and inspect the empty cartridge
Apply the qualified route to the compatible boundary
Load lyophilised reagents under controlled aseptic conditions
Close, pouch and verify package integrity
One possible process architecture surfaced by the research. It is a hypothesis for feasibility testing, not a validated manufacturing instruction.
TECHNOLOGY SCOUTING / IMPLEMENTATION QUESTIONS AND DELIVERY
Implementation question matrix
Work package | Question to resolve | Example evidence or test output |
|---|---|---|
Materials and function | Does the route alter polymer dimensions, optical transmission, seal strength, adhesive performance, channel wetting or fluidic timing? | Coupon and assembled cartridge results, optical comparison, leak or burst data and functional assay performance. |
Reagent stability | Does direct or indirect exposure change enzyme activity, control response, calibration or accelerated ageing behaviour? | Dose or exposure response curve, assay shift against acceptance limits and stability observations. |
Microbiological process | Can the modality reach the hardest location in the selected load and support the required sterility assurance approach? | Product family rationale, challenge location, dose or concentration mapping and validation protocol outline. |
Packaging and shelf life | Does the sterile barrier permit processing and retain integrity through distribution and the intended shelf life? | Material compatibility, seal integrity, ageing and transport test plan. |
Regulatory change assessment | What submission, master file, standard or additional evidence route applies to the proposed change? | Regulatory question list and documented basis for discussion with qualified regulatory specialists. |
External capability | Which contract providers or specialist laboratories have the relevant chamber, source, load configuration, analytical methods and validation experience? | Provider capability tracker and questions for a controlled technical outreach stage. |
What the client would receive
- A documented scouting brief containing the device boundary, non negotiable requirements, search grammar, exclusions and evidence cut off date.
- A candidate field and screening log showing 46 initial leads, 17 in scope candidates and eight detailed evidence cards in this hypothetical example.
- Eight candidate evidence cards covering technical relevance, regulatory context, maturity signals, provider or access pathway, evidence limitations and the next question.
- A route triage view with advance, watch and hold logic, plus the sterilisation boundary option and its manufacturing implications.
- An implementation question matrix that can be handed to R&D, quality, microbiology, regulatory and external laboratory or provider teams.
- A final decision briefing and editable research workbook with traceable source links, observation dates and status rationale.
TECHNOLOGY SCOUTING / DELIVERY AND WEBSITE PRESENTATION
Indicative delivery
A focused assignment of this type could be delivered in approximately five weeks: scope and product boundary in week one; modality, standards and candidate scanning in weeks one and two; evidence cards and first screening in week three; cross functional challenge session in week four; and final action queue, question matrix and briefing in week five. Delivery could include a kickoff, one mid scan checkpoint, a technical challenge workshop and a final presentation.
Timeline note: Timing is illustrative and depends on product complexity, geographic and language scope, source accessibility and the depth of candidate review. It excludes laboratory testing and provider outreach. If primary research or external validation is added, timing will also depend on specialist response, facility availability and test lead times.
WEBSITE PRESENTATION SUGGESTION Open the example with an interactive cartridge boundary map. Visitors can select Hardware, Reagents, Package or Process to see which route remains relevant, what evidence supports it and the next question. Follow with the route triage matrix and a compact five week delivery timeline. Use technical line art or component photography, not decorative AI imagery.
Let’s discuss your technology scouting question
August Research can structure the search around the materials, process limits, regulatory context and external capability that define your real decision, then show which options deserve deeper technical work.
Note: This engagement, device profile, candidate counts, screening statuses, figures and outputs are hypothetical and are not presented as client work or research findings. The solution routes are grounded in publicly available regulatory and standards information, but their suitability for any device would require product specific validation and qualified regulatory review.